#136 1960 · Frances Oldham Kelsey / FDA · Pharmaceutical regulation
The rule said a drug application had to be rejected within 60 days or it was automatically approved — so instead of trying to reject a well-funded drug outright, Kelsey just never let the clock run out.
问题
the formal process governing a decision is structurally biased toward a default outcome you believe is wrong, and directly overriding that default invites resistance you may not be able to win
背景
Under 1960s FDA rules, a New Drug Application was automatically approved for market if the agency's reviewer failed to formally reject it within 60 days of submission — a structure that put the burden on a reviewer to actively stop a drug rather than requiring the manufacturer to actively prove safety, meaning inaction by the FDA defaulted to approval, not caution. Frances Oldham Kelsey, in her first weeks as a new FDA medical officer in September 1960, was assigned to review Merrell Pharmaceuticals' application for thalidomide, a sedative marketed in Europe as safe for pregnant women experiencing morning sickness.
Kelsey found the clinical safety data Merrell submitted unconvincing rather than clearly conclusive — not proof the drug was dangerous, but not proof it was safe either. Rejecting the application outright against a well-funded, aggressive pharmaceutical company with only ambiguous evidence risked a fight she might not win under a regulatory structure built to favor approval by default; Merrell's sales representatives began pressuring her office directly once the delay began.
换别人会怎么做
The standard way for a regulator to block a drug she distrusts is to reject the application outright, on the record, and defend that judgment against the manufacturer's pressure. That path was mostly closed to Kelsey: as a brand-new reviewer with no long track record at the agency, an outright rejection of a drug already approved and selling in dozens of other countries would have been an aggressive, appealable call resting on her own clinical instinct, against a company actively lobbying her superiors and pushing for a decision before her authority to make one was fully established.
他们看到了什么
Kelsey saw that the FDA's own 60-day automatic-approval clock, ordinarily an administrative deadline working against a reviewer with doubts, contained a procedural escape hatch: an application could be ruled 'incomplete' if it lacked adequate safety evidence, which reset the clock and required the company to resubmit. She didn't need to win an argument about thalidomide's safety at all; she only needed to keep finding the submitted evidence genuinely insufficient, repeatedly, using the standard the law already required the company to meet.
那一手
Rather than issue an outright rejection, Kelsey used the review process's own legitimate mechanism against the default: each time Merrell's submitted safety data fell short of what she considered scientifically adequate, she formally requested additional data, resetting or extending the clock and keeping the application in an unapproved state without ever needing to win a definitive up-or-down confrontation over the drug's safety.
为什么管用
By treating each thalidomide submission as procedurally incomplete rather than substantively unsafe, Kelsey never had to prove a claim she couldn't yet prove — that the drug caused harm — she only had to point out, correctly and defensibly, that the company's own animal and clinical data didn't meet the evidentiary bar the application process already demanded. That made her repeated holds nearly impossible to overturn on appeal: the company could lobby her supervisors all it wanted, but it couldn't argue around a regulatory clock that had legitimately not started because the file was, by the letter of the rule, still incomplete. The delay bought exactly enough time for the German and Australian case reports linking thalidomide to severe birth defects to surface and confirm what her data gaps had only hinted at, at which point the same procedural machinery that had merely stalled the drug now kept it off the U.S. market outright.
值了多少
Kelsey's repeated requests for better evidence delayed thalidomide's US approval for roughly 19 months, during which independent researchers in Germany and Australia established a clear link between thalidomide and severe birth defects, affecting an estimated several thousand babies born to mothers who had taken the drug in Europe and elsewhere. Thalidomide was never approved or marketed in the United States, sparing American mothers and infants from the disaster unfolding abroad.
什么时候会失灵
This mechanism only works when the reviewer has genuine, defensible procedural grounds to invoke — a regulator who declares an application 'incomplete' without real evidentiary gaps is exposed to the same override risk as an outright rejection, since the excuse collapses under scrutiny. It also depends on the underlying process having a built-in default that favors delay when properly invoked (here, an automatic-approval clock that could legitimately be reset) rather than one that favors approval regardless of an official's stated doubts. And it is a stalling tactic, not a permanent block: had the confirming evidence from Europe and Australia arrived years later instead of within the year, the same procedural holds might eventually have been exhausted, leaving the drug approved anyway once the company filed a technically complete application.
后来呢
The thalidomide episode, and Kelsey's role in it, directly drove passage of the 1962 Kefauver-Harris Drug Amendments, which fundamentally rewrote US drug approval to require manufacturers to affirmatively prove both safety and efficacy before market approval rather than defaulting to approval absent a rejection — Kelsey is now the textbook case in regulatory and public health circles for how a reviewer can use a biased process's own procedural machinery to hold a line no direct confrontation could have held.
资料来源
- [1]Frances Oldham Kelsey: Medical reviewer famous for averting a public health tragedyUS Food and Drug Administration, 2020fda.gov
- [2]The Devil in the Details, Chapter One: The Doctor Who Said No to ThalidomideScientific American, 2020scientificamerican.com